Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zachary Simmons

Clinical Neurophysiology Hershey, PA Medical Doctor

NPI 1790733814 CMS profile 670724

500 University Dr, Entrance B, Hershey, PA 17033

Open in the dashboard

General payments

$43,087

29 records reported · program years 2019–2025

Research payments

$16,115

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$356,709 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Zachary Simmons of Hershey, PA is reported in the CMS Open Payments database as having received $43,087 across 29 general payments and $16,115 in research payments paid to them. Separately, studies naming them as principal investigator received $356,709 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,426 4
2025 Research $1,225 1
2024 General $6,181 5
2024 Research $875 1
2023 General $8,924 8
2023 Research $2,013 1
2022 General $950 1
2022 Research $1,050 1
2021 General $1,092 1
2021 Research $4,428 3
2020 General $1,514 10
2020 Research $4,425 5
2019 Research $2,100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zachary Simmons
  • Clinical Neurophysiology median
  • Middle half of Clinical Neurophysiology
  • National median

In program year 2025, general payments to Zachary Simmons were reported at $24,426. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.

Show as a table
Year Zachary Simmons Clinical Neurophysiology median Middle half National median
2019 $0 $306 $88–$1,636 $163
2020 $1,514 $299 $85–$1,847 $114
2021 $1,092 $325 $96–$2,308 $132
2022 $950 $395 $106–$1,957 $149
2023 $8,924 $388 $120–$1,718 $160
2024 $6,181 $471 $137–$1,931 $164
2025 $24,426 $435 $121–$1,917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Insmed, Inc. $23,951 3 payments
  2. Corcept Therapeutics $8,431 6 payments
  3. Amylyx Pharmaceuticals, Inc. $8,099 9 payments
  4. Mitsubishi Tanabe Pharma Development America, Inc. $1,514 10 payments
  5. Sanofi-Aventis U.S. LLC $1,092 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $34,787 12 payments
  2. Honoraria $6,738 6 payments
  3. Travel and Lodging $1,121 4 payments
  4. Food and Beverage $442 7 payments
Products named General payments · program years 2019–2025
  1. RELYVRIO Neurology $6,786 7 payments
  2. Korlym $3,088 2 payments
  3. RELYVRIO Neurology $1,313 2 payments
  4. Arikayce $557 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $12,915 9 payments
  2. Alexion Pharmaceuticals, Inc. $3,200 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

576

Median for Neurology: 833

Drug cost

$4,142,405

Median for Neurology: $202,670

Branded share of claims

37.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 57 $1,502,159
Radicava Ors Edaravone Brand 70 $1,044,931
Firdapse Amifampridine Phosphate Brand 13 $737,648
Relyvrio Sod Phenylbutyrat/Taurursodiol Brand 38 $471,598
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 23 $290,030
Riluzole Generic 176 $54,868
Mestinon Pyridostigmine Bromide Brand 15 $36,087
Baclofen Generic 37 $1,808
Mycophenolate Mofetil Generic 14 $959
Glycopyrrolate Generic 17 $727

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$10,299

Medicare's payments for the services billed

Medicare patients

57

Average age 71

Services billed

195

21 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 54%
Ischemic heart disease 25%
Diabetes 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELYVRIO
  • Amylyx Pharmaceuticals, Inc. $1,313
$1,313 38 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Neurophysiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record